Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Immunol ; 48(2): 330-343, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29143318

RESUMO

One factor that significantly contributes to renal allograft loss is chronic calcineurin inhibitor (CNI) nephrotoxicity (CIN). Among other factors, the complement (C-) system has been proposed to be involved CIN development. Hence, we investigated the impact of CNIs on intracellular signalling and the effects on the C-system in human renal tubule cells. In a qPCR array, CNI treatment upregulated C-factors and downregulated SOCS-3 and the complement inhibitors CD46 and CD55. Additionally, ERK1/-2 was required for these regulations. Following knock-down and overexpression of SOCS-3, we found that SOCS-3 inhibits ERK1/-2 signalling. Finally, we assessed terminal complement complex formation, cell viability and apoptosis. Terminal complement complex formation was induced by CNIs. Cell viability was significantly decreased, whereas apoptosis was increased. Both effects were reversed under complement component-depleted conditions. In vivo, increased ERK1/-2 phosphorylation and SOCS-3 downregulation were observed at the time of transplantation in renal allograft patients who developed a progressive decline of renal function in the follow-up compared to stable patients. The progressive cohort also had lower total C3 levels, suggesting higher complement activity at baseline. In conclusion, our data suggest that SOCS-3 inhibits CNI-induced ERK1/-2 signalling, thereby blunting the negative control of C-system activation.


Assuntos
Inibidores de Calcineurina/efeitos adversos , Proteínas do Sistema Complemento/metabolismo , Ciclosporina/efeitos adversos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/metabolismo , Rejeição de Enxerto/metabolismo , Nefropatias/metabolismo , Transplante de Rim , Túbulos Renais/efeitos dos fármacos , Proteína 3 Supressora da Sinalização de Citocinas/metabolismo , Tacrolimo/efeitos adversos , Idoso , Idoso de 80 Anos ou mais , Apoptose , Antígenos CD55/metabolismo , Inibidores de Calcineurina/uso terapêutico , Linhagem Celular , Sobrevivência Celular , Complexo de Ataque à Membrana do Sistema Complemento/metabolismo , Ciclosporina/uso terapêutico , Feminino , Regulação da Expressão Gênica , Humanos , Nefropatias/terapia , Túbulos Renais/patologia , Sistema de Sinalização das MAP Quinases , Masculino , Proteína Cofatora de Membrana/metabolismo , Pessoa de Meia-Idade , Fosforilação , RNA Interferente Pequeno/genética , Proteína 3 Supressora da Sinalização de Citocinas/genética , Tacrolimo/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...